Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Español para el Tratamiento Oncologico (GGETO).
27 patients with FIGO stage III-IV endometrial adenocarcinoma were entered in a phase II trial evaluating activity and safety of epirubicin given at 80 mg/m2 intravenously every 3 weeks. 2 complete remissions (including a pathological one) and 5 partial responses were observed for a response rate of 26% (95% confidence interval 11-46). The median time to progression and median survival for all treated patients was 6 and 9.5 months, respectively. Treatment was well tolerated. Haematological toxicity was mild. The median total cumulative dose of epirubicin was 480 mg/m2 (160-880) and cardiac toxicity was not observed. Further studies with higher doses of epirubicin in combination with other active drugs are indicated.
Calero
F
F
Department of Gynecology, Hospital Maternal La Paz, Madrid, Spain.
Asins-Codoñer
E
E
Jimeno
J
J
Rodriguez Escudero
F
F
Mendaña
J
J
Iglesias
J
J
Matía
F
F
Armas
A
A
Díaz-Castellanos
R
R
Garzón
J
J
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D004717:Endometrium / Q000473:pathology; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D014621:Vagina / Q000473:pathology
D015251:Epirubicin